2018-2023 Global Glioblastoma Multiforme Treatment (GBM) Market Report (Status and Outlook)

August 2018 | 117 pages | ID: 233B87CC783EN
LP Information

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

In this report, LP Information studies the present scenario (with the base year being 2017) and the growth prospects of global Glioblastoma Multiforme Treatment (GBM) market for 2018-2023.

Glioblastoma is a fast-growing, aggressive type of central nervous system tumor that forms on the supportive tissue of the brain.
Global glioblastoma multiforme treatment market is expected to witness significant growth over the forecast period owing to the rising incidence of oncology diseases and rising geriatric population base.
Over the next five years, LPI(LP Information) projects that Glioblastoma Multiforme Treatment (GBM) will register a xx% CAGR in terms of revenue, reach US$ xx million by 2023, from US$ xx million in 2017.

This report presents a comprehensive overview, market shares and growth opportunities of Glioblastoma Multiforme Treatment (GBM) market by product type, application, key companies and key regions.

To calculate the market size, LP Information considers value generated from the sales of the following segments:

Segmentation by product type:

• Chemotherapy
• Radiotherapy
• Molecular biotechnology

Segmentation by application:

• Bevacozumab
• Carmustine
• Temozolomide

We can also provide the customized separate regional or country-level reports, for the following regions:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Spain
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report:

• Merck
• Teva Pharmaceutical
• Arbor Pharmaceuticals
• Sun Pharmaceutical
• Roche

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key players and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives

• To study and analyze the global Glioblastoma Multiforme Treatment (GBM) market size by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2023.
• To understand the structure of Glioblastoma Multiforme Treatment (GBM) market by identifying its various subsegments.
• Focuses on the key global Glioblastoma Multiforme Treatment (GBM) players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
• To analyze the Glioblastoma Multiforme Treatment (GBM) with respect to individual growth trends, future prospects, and their contribution to the total market.
• To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
• To project the size of Glioblastoma Multiforme Treatment (GBM) submarkets, with respect to key regions (along with their respective key countries).
• To analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market.
• To strategically profile the key players and comprehensively analyze their growth strategies.

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Economic Indicators
1.6 Currency Considered

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Glioblastoma Multiforme Treatment (GBM) Market Size 2013-2023
  2.1.2 Glioblastoma Multiforme Treatment (GBM) Market Size CAGR by Region
2.2 Glioblastoma Multiforme Treatment (GBM) Segment by Type
  2.2.1 Chemotherapy
  2.2.2 Radiotherapy
  2.2.3 Gene therapy
  2.2.4 Molecular biotechnology
2.3 Glioblastoma Multiforme Treatment (GBM) Market Size by Type
  2.3.1 Global Glioblastoma Multiforme Treatment (GBM) Market Size Market Share by Type (2013-2018)
  2.3.2 Global Glioblastoma Multiforme Treatment (GBM) Market Size Growth Rate by Type (2013-2018)
2.4 Glioblastoma Multiforme Treatment (GBM) Segment by Application
  2.4.1 Bevacozumab
  2.4.2 Carmustine
  2.4.3 Temozolomide
2.5 Glioblastoma Multiforme Treatment (GBM) Market Size by Application
  2.5.1 Global Glioblastoma Multiforme Treatment (GBM) Market Size Market Share by Application (2013-2018)
  2.5.2 Global Glioblastoma Multiforme Treatment (GBM) Market Size Growth Rate by Application (2013-2018)

3 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT (GBM) BY PLAYERS

3.1 Global Glioblastoma Multiforme Treatment (GBM) Market Size Market Share by Players
  3.1.1 Global Glioblastoma Multiforme Treatment (GBM) Market Size by Players (2016-2018)
  3.1.2 Global Glioblastoma Multiforme Treatment (GBM) Market Size Market Share by Players (2016-2018)
3.2 Global Glioblastoma Multiforme Treatment (GBM) Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
  3.3.1 Competition Landscape Analysis
  3.3.2 Concentration Ratio (CR3, CR5 and CR10) (2016-2018)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion

4 GLIOBLASTOMA MULTIFORME TREATMENT (GBM) BY REGIONS

4.1 Glioblastoma Multiforme Treatment (GBM) Market Size by Regions
4.2 Americas Glioblastoma Multiforme Treatment (GBM) Market Size Growth
4.3 APAC Glioblastoma Multiforme Treatment (GBM) Market Size Growth
4.4 Europe Glioblastoma Multiforme Treatment (GBM) Market Size Growth
4.5 Middle East & Africa Glioblastoma Multiforme Treatment (GBM) Market Size Growth

5 AMERICAS

5.1 Americas Glioblastoma Multiforme Treatment (GBM) Market Size by Countries
5.2 Americas Glioblastoma Multiforme Treatment (GBM) Market Size by Type
5.3 Americas Glioblastoma Multiforme Treatment (GBM) Market Size by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Key Economic Indicators of Few Americas Countries

6 APAC

6.1 APAC Glioblastoma Multiforme Treatment (GBM) Market Size by Countries
6.2 APAC Glioblastoma Multiforme Treatment (GBM) Market Size by Type
6.3 APAC Glioblastoma Multiforme Treatment (GBM) Market Size by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Countries

7 EUROPE

7.1 Europe Glioblastoma Multiforme Treatment (GBM) by Countries
7.2 Europe Glioblastoma Multiforme Treatment (GBM) Market Size by Type
7.3 Europe Glioblastoma Multiforme Treatment (GBM) Market Size by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Spain
7.10 Key Economic Indicators of Few Europe Countries

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Glioblastoma Multiforme Treatment (GBM) by Countries
8.2 Middle East & Africa Glioblastoma Multiforme Treatment (GBM) Market Size by Type
8.3 Middle East & Africa Glioblastoma Multiforme Treatment (GBM) Market Size by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers and Impact
  9.1.1 Growing Demand from Key Regions
  9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends

10 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT (GBM) MARKET FORECAST

10.1 Global Glioblastoma Multiforme Treatment (GBM) Market Size Forecast (2018-2023)
10.2 Global Glioblastoma Multiforme Treatment (GBM) Forecast by Regions
  10.2.1 Global Glioblastoma Multiforme Treatment (GBM) Forecast by Regions (2018-2023)
  10.2.2 Americas Market Forecast
  10.2.3 APAC Market Forecast
  10.2.4 Europe Market Forecast
  10.2.5 Middle East & Africa Market Forecast
10.3 Americas Forecast by Countries
  10.3.1 United States Market Forecast
  10.3.2 Canada Market Forecast
  10.3.3 Mexico Market Forecast
  10.3.4 Brazil Market Forecast
10.4 APAC Forecast by Countries
  10.4.1 China Market Forecast
  10.4.2 Japan Market Forecast
  10.4.3 Korea Market Forecast
  10.4.4 Southeast Asia Market Forecast
  10.4.5 India Market Forecast
  10.4.6 Australia Market Forecast
10.5 Europe Forecast by Countries
  10.5.1 Germany Market Forecast
  10.5.2 France Market Forecast
  10.5.3 UK Market Forecast
  10.5.4 Italy Market Forecast
  10.5.5 Russia Market Forecast
  10.5.6 Spain Market Forecast
10.6 Middle East & Africa Forecast by Countries
  10.6.1 Egypt Market Forecast
  10.6.2 South Africa Market Forecast
  10.6.3 Israel Market Forecast
  10.6.4 Turkey Market Forecast
  10.6.5 GCC Countries Market Forecast
10.7 Global Glioblastoma Multiforme Treatment (GBM) Forecast by Type
10.8 Global Glioblastoma Multiforme Treatment (GBM) Forecast by Application

11 KEY PLAYERS ANALYSIS

11.1 Merck
  11.1.1 Company Details
  11.1.2 Glioblastoma Multiforme Treatment (GBM) Product Offered
  11.1.3 Merck Glioblastoma Multiforme Treatment (GBM) Revenue, Gross Margin and Market Share (2016-2018)
  11.1.4 Main Business Overview
  11.1.5 Merck News
11.2 Teva Pharmaceutical
  11.2.1 Company Details
  11.2.2 Glioblastoma Multiforme Treatment (GBM) Product Offered
  11.2.3 Teva Pharmaceutical Glioblastoma Multiforme Treatment (GBM) Revenue, Gross Margin and Market Share (2016-2018)
  11.2.4 Main Business Overview
  11.2.5 Teva Pharmaceutical News
11.3 Arbor Pharmaceuticals
  11.3.1 Company Details
  11.3.2 Glioblastoma Multiforme Treatment (GBM) Product Offered
  11.3.3 Arbor Pharmaceuticals Glioblastoma Multiforme Treatment (GBM) Revenue, Gross Margin and Market Share (2016-2018)
  11.3.4 Main Business Overview
  11.3.5 Arbor Pharmaceuticals News
11.4 Sun Pharmaceutical
  11.4.1 Company Details
  11.4.2 Glioblastoma Multiforme Treatment (GBM) Product Offered
  11.4.3 Sun Pharmaceutical Glioblastoma Multiforme Treatment (GBM) Revenue, Gross Margin and Market Share (2016-2018)
  11.4.4 Main Business Overview
  11.4.5 Sun Pharmaceutical News
11.5 Roche
  11.5.1 Company Details
  11.5.2 Glioblastoma Multiforme Treatment (GBM) Product Offered
  11.5.3 Roche Glioblastoma Multiforme Treatment (GBM) Revenue, Gross Margin and Market Share (2016-2018)
  11.5.4 Main Business Overview
  11.5.5 Roche News

...

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES AND FIGURES

Table Product Specifications of Glioblastoma Multiforme Treatment (GBM)
Figure Glioblastoma Multiforme Treatment (GBM) Report Years Considered
Figure Market Research Methodology
Figure Global Gli